PMID- 34854474
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220515
IS  - 1521-4141 (Electronic)
IS  - 0014-2980 (Linking)
VI  - 52
IP  - 4
DP  - 2022 Apr
TI  - Novel approach to monitor intravenous immunoglobulin pharmacokinetics in humans 
      using polymorphic determinants in IgG1 constant domains.
PG  - 609-617
LID - 10.1002/eji.202149653 [doi]
AB  - Clinical efficacy of intravenous immunoglobulin treatment (IVIg) is related to 
      its pharmacokinetic (PK) profile. Its usual evaluation, by measuring serum total 
      IgG levels, is imprecise, because IVIg cannot be distinguished from endogenous 
      IgG. We developed ELISAs to specifically monitor the PK of IVIg using the 
      polymorphic determinants G1m(a), G1m(x), and G1m(f). The specificity of the IgG1 
      allotype assays was sufficient to determine IVIg concentrations as low as 0.1 
      mg/mL in sera from individuals not expressing the respective markers. IVIg was 
      quantified in posttreatment serum from patients with Guillain-Barre syndrome 
      (GBS) by measuring IgG1 allotypes not expressed endogenously. After serotyping, 
      27/28 GBS patients were found eligible for IVIg monitoring using one or two 
      genetic markers. In 17 cases, IVIg levels could be determined by both anti-G1m(a) 
      and anti-G1m(x) measurement, showing significant correlation. Longitudinal 
      monitoring of IVIg PK in seven GBS patients showed potential differences in 
      clearance of total IgG versus IVIg-derived IgG, highlighting that total IgG 
      measurements may not accurately reflect IVIg PK. To summarize, anti-IgG1 allotype 
      assays can discriminate between endogenous IgG and therapeutic polyclonal IgG. 
      These assays will be an important tool to better understand the variability in 
      IVIg PK and treatment response of all patients treated with IVIg.
CI  - (c) 2021 Wiley-VCH GmbH.
FAU - van Tilburg, Sander J
AU  - van Tilburg SJ
AD  - Department of Immunology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
FAU - Jacobs, Bart C
AU  - Jacobs BC
AD  - Department of Immunology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
FAU - Ooijevaar-de Heer, Pleuni
AU  - Ooijevaar-de Heer P
AD  - Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, 
      Amsterdam, The Netherlands.
FAU - Fokkink, Willem-Jan R
AU  - Fokkink WR
AD  - Department of Immunology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
AD  - Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
FAU - Huizinga, Ruth
AU  - Huizinga R
AD  - Department of Immunology, Erasmus MC University Medical Center, Rotterdam, The 
      Netherlands.
FAU - Vidarsson, Gestur
AU  - Vidarsson G
AD  - Department of Experimental Immunohematology, Sanquin Research and Landsteiner 
      Laboratory, Amsterdam, The Netherlands.
FAU - Rispens, Theo
AU  - Rispens T
AUID- ORCID: 0000-0001-9600-1312
AD  - Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211224
PL  - Germany
TA  - Eur J Immunol
JT  - European journal of immunology
JID - 1273201
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Biomarkers
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - *Immunoglobulin G
MH  - *Immunoglobulins, Intravenous/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Guillain-Barre syndrome
OT  - IgG1 allotypes
OT  - Intravenous immunoglobulin
OT  - Monoclonal antibody
OT  - Pharmacokinetic
EDAT- 2021/12/03 06:00
MHDA- 2022/04/08 06:00
CRDT- 2021/12/02 08:48
PHST- 2021/11/20 00:00 [revised]
PHST- 2021/09/24 00:00 [received]
PHST- 2021/12/03 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
PHST- 2021/12/02 08:48 [entrez]
AID - 10.1002/eji.202149653 [doi]
PST - ppublish
SO  - Eur J Immunol. 2022 Apr;52(4):609-617. doi: 10.1002/eji.202149653. Epub 2021 Dec 
      24.